These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24347382)

  • 1. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Becker A; Eichelberg C; Sun M
    Cancer; 2014 Jan; 120(1):7-10. PubMed ID: 24347382
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Halabi S; Rini BI; Escudier B; Stadler WM; Small EJ
    Cancer; 2015 Jun; 121(11):1906. PubMed ID: 25677867
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
    Becker A; Eichelberg C; Sun M
    Cancer; 2015 Jun; 121(11):1906-7. PubMed ID: 25677986
    [No Abstract]   [Full Text] [Related]  

  • 4. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 5. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 6. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
    Bradshaw MJ; Cheville JC; Croghan GA
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149
    [No Abstract]   [Full Text] [Related]  

  • 7. Current treatment of renal cell carcinoma.
    De Mulder PH; van Herpen CM; Mulders PA
    Ann Oncol; 2004; 15 Suppl 4():iv319-28. PubMed ID: 15477330
    [No Abstract]   [Full Text] [Related]  

  • 8. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 9. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.
    Nathan PD; Gore ME; Eisen TG
    J Clin Oncol; 2002 Mar; 20(5):1429-30. PubMed ID: 11870194
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting survival of patients with metastatic renal cell carcinoma.
    Motzer RJ; Mazumdar M
    Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
    Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
    Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon.
    Alikhan M; Spencer HJ; Kohli M
    J Clin Oncol; 2005 Sep; 23(25):6267-8; author reply 6268-9. PubMed ID: 16135500
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-VEGF therapy for renal cell carcinoma.
    Escudier B
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):530-1. PubMed ID: 17679926
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
    Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
    Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis.
    Akaza H; Kawai K; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):684-9. PubMed ID: 20382632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined interferon and vinblastine treatment in advanced renal cell cancer.
    Kellokumpu-Lehtinen P; Jantunen I; Flander M; Johansson R; Nordman E
    Acta Oncol; 1995; 34(7):975-7. PubMed ID: 7492395
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
    Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
    J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.